Home » Noven Announces Phase III Results for Investigational Non-Hormonal Therapy for Vasomotor Symptoms
Noven Announces Phase III Results for Investigational Non-Hormonal Therapy for Vasomotor Symptoms
Noven Pharmaceuticals announced top-line results from the first of two planned Phase III clinical studies evaluating low-dose mesylate salt of paroxetine for the treatment of vasomotor symptoms associated with menopause.
Yahoo! Finance
Yahoo! Finance
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May